PUBBLICATO IL NUOVO NUMERO DELLA WHO PHARMACEUTICAL NEWSLETTER

Fonte: WHO. N 3, giugno 2017

E' disponibile il nuovo numero della WHO Pharmaceutical newsletter.

In questo numero:

REGULATORY MATTERS
• Bevacizumab
• Canagliflozin
• Caspofungin
• Clopidogrel
• Codeine and tramadol
• Denosumab
• Dipeptidylpeptidase-4 (DPP-4) inhibitors
• Factor VIII medicines
• General anaesthetic and sedation drugs
• Ingenol mebutate
• Interferon alfa and interferon beta
• Iodinated contrast medium
• Pembrolizumab
• Ticagrelor
• Valproate

SAFETY OF MEDICINE
• Crizotinib
• Direct-acting antivirals (DAAs)
• Fluconazole
• Flutamide
• Multiple sclerosis therapies
• Ponatinib
• Testosterone
• Viekira PAK® and Technivie® (direct-acting antivirals)
• Ibrutinib and pneumonitis

SIGNAL
• Pregabalin and visual colour distortions
• SGLT-2 inhibitors and genital pruritus

FEATURE
• Pilot Mobile ‘APP’ for reporting suspected adverse drug reactions launched in Burkina Faso and Zambia
• Introducing a New Member in the WHO Programme for International Drug Monitoring (WHO PIDM): Paraguay